Geron Corporation: Uncovering a Hidden Value Opportunity Amidst Bearish Comments
GERN’s Rytelo: A Promising Start with Uncertain Future GERN, a leading biotech company, reported impressive sales growth for its flagship product Rytelo in the last quarter of 2024. With a net product revenue increase of 68% from Q3’24, the company reached a revenue of $47.5M in Q4’24. This growth was driven by strong market demand…